摘要
目的:探讨Graves病患者131I治疗前后可溶性细胞凋亡相关蛋白Fas(sFas)和促甲状腺激素受体抗体(TRAb)水平的改变及其相关性。方法:采用酶联免疫吸附试验(ELISA)和放射免疫分析法(RIA)分别检测30例GD患者131I治疗前后血清sFas和TRAb水平,并进行相关性分析,20例年龄与性别相匹配的健康者作为正常对照。结果:GD患者血清sFas水平(3.05±1.25 ng/ml)、TRAb水平(40.4±7.59 ng/ml)显著高于对照组(1.69±0.48 ng/ml、7.10±2.62 ng/ml)(P<0.01、P<0.01);131I治疗后,甲状腺功能恢复正常,症状缓解,sFas(2.11±0.89 ng/ml)、TRAb(16.7±5.78 ng/ml)水平明显下降,但仍高于对照组(P<0.05、P<0.01);sFas与TRAb呈正相关(P<0.01)。结论:GD患者体内存在sFas和TRAb异常表达,131I能有效抑制GD患者自身免疫,sFas和TRAb可能可作为GD诊断和疗效观察的良好指标。
Objective：Study on changes and correlation of the serum sFas and anti-hyrotropin receptor antibody（TRAb） in Patietns with Graves′disease before and After Treated With 131I.Methods：Using the method of enzyme-linked immunosorbent assay（ELISA） and radioimmunoassay（RIA）,the serum levels of sFas and TRAb of GD 30 patients were measured before and after 131Itherapy,20 age-and sex-matched healthy subjects served as controls,and the results were compared with that of the control group.Results：The serum sFas levels（3.05±1.25） ng/ml and TRAb levels（40.4±7.59）ng/ml of GD patients were significantly higher than that of the control group（1.69±0.48 ng/ml、7.10±2.62 ng/ml）（P〈0.01）.The serum sFas（2.11±0.89）ng/ml and TRAb（16.7±5.78）ng/ml tended to decrease after the medication of radio-active 131I,but still higher than that of the normal controls（P〈0.05、P〈0.01）.The concentration of serum sFas was positively correlated with the titers of TRAb（r=0.678 P〈0.01）.Conclusion：Abnormal serum concentration of sFas and TRAb can be observed in patients with GD,Successful 131I therapy would effectively suppress the auto-immune status in GD patients,and sFas and TRAb were practical laboratory diagnostic creterion for GD.
出处
《中国卫生检验杂志》
CAS
2011年第4期935-936,共2页
Chinese Journal of Health Laboratory Technology
